secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImageneBio, Inc. (IMA)
CIK:        0001835579
Form:       8-K
Filed at:   2025-07-16T23:59:59+00:00
Accession:  0001193125-25-159910
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Ikena Oncology amends executive’s equity vesting terms tied to pending Inmagene merger
--------------------------------------------------------------------------------

- Effective July 15, 2025, Ikena Oncology amended employment agreement with Dr. Jotin Marango, an executive officer.
- Amendment provides for full acceleration of time-based equity awards if termination without cause or resignation during change in control period.
- Change in control period began March 18, 2025 (initial S-4 filing for merger with Inmagene) and ends 12 months post-merger.
- Accelerated vesting effective later of termination date or change in control; forfeiture of unvested portions delayed until that date.
- Contemplated merger with Inmagene Biopharmaceutics was announced December 23, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835579/000119312525159910/0001193125-25-159910-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835579/000119312525159910/d948992d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-159910

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer